A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 9, 2013, Pages 1577-1582

  Stein, Stacey M ^a   Tiersten, Amy ^b   Hochster, Howard S ^a   Blank, Stephanie V ^c   Pothuri, Bhavana ^c   Curtin, John ^c   Shapira, Ilan ^c,d   Levinson, Benjamin ^c   Ivy, Percy ^e   Joseph, Benson ^b   Guddati, Achuta Kumar ^f   Muggia, Franco ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Medical Oncology   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Continuous infusion; Ovarian cancer; Oxalipatin; Phase 2; Topotecan

Indexed keywords

CA 125 ANTIGEN; CREATININE; OXALIPLATIN; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIFE EXPECTANCY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INFUSION PUMPS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 84888309055     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a809e0     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
3. Huang L, Cronin KA, Johnson KA, et al. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer. 2008; 112: 2289-2300.
4. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351: 2519-2529.
5. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998; 25: 4-12.
6. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996; 52: 1855-1865.
7. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol. 1996; 7: 1065-1070.
8. Hochster H, Wadler S, Runowicz C, et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol. 1999; 17: 2553-2561.
9. Hochster H, Liebes L, Speyer J, et al. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res. 1997; 3: 1245-1252.
10. Hochster HS, Plimack ER, Mandeli J, et al.; New York Gynecologic Oncology Group (and phase II consortium) and the Eastern Cooperative Oncology. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. Gynecol Oncol. 2006; 100: 324-329.
11. Mirchandani D, Hochster H, Hamilton A, et al. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res. 2005; 11: 5912-5919.
12. Hochster H, Chen TT, Lu JM, et al. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol. 2008; 108: 500-504.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
14. Rustin GJ, Bast RC Jr, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004; 10: 3919-3926.
15. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003; 21:187sY193s.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. 1989; 10: 1-10.
17. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-3322.
18. Tortora G, Ciardiello F, Damiano V, et al. Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. Ann Oncol. 2002; 13: 392-398.
19. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24: 4699-4707.
20. Murgia V, Sorio R, Griso C, et al. Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer. Int J Gynecol Cancer. 2010; 20: 953-957.
21. Ray-Coquard I,Weber B, Cretin J, et al. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer. 2009; 100: 601-607.
22. Guarneri V, Piacentini F, Barbieri E, et al. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010; 117: 152-158.
23. Parmar MK, Lederman JA, Colombo N, et al.; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361: 2099-2106.
24. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010; 28: 3323-3329.
25. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012; 107: 588-591.
26. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 30: 2039-2045.
27. Eric Pujade-Lauraine FH, Weber B, Reuss A; AURELIA Investigators. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol. 2012; 30; abstr LBA5002.